Blue Owl Capital Holdings LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Blue Owl Capital Holdings LP reported 44 stock positions worth $500.6 million. Its top holding was Robinhood Markets Class A (HOOD) at 10.8% of the portfolio, followed by Cullinan Therapeutics (CGEM, 10.0%) and Pliant Therapeutics (PLRX, 8.9%). Compared with Q4 2023, it opened 6 new positions, sold out of 4, added to 15 and reduced 5. The biggest buy was Engene (ENGN, shares +99%) and the biggest sale Syros Pharmaceuticals (SYRS, shares −77%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001858703
- Portfolio Value
- $500.6M (Q1 2024)
- SEC Filing
- 0000950123-24-005559 ↗ filed May 15, 2024
Holdings Value
Holdings 44 stocks · $500.6M
| HOOD Robinhood Markets Inc. Class A | 10.78% | 4,237,409 | $54.0M | No change |
| CGEM Cullinan Therapeutics Inc. | 9.96% | 2,924,842 | $49.8M | Reduce -14.5% |
| PLRX Pliant Therapeutics Inc. | 8.94% | 3,004,199 | $44.8M | No change |
| ENGN Engene Holdings Inc. | 8.33% | 2,461,350 | $41.7M | Add +99.3% |
| TRML Tourmaline Bio Inc. | 6.39% | 1,447,401 | $32.0M | Add +8.6% |
| OBDC Blue Owl Capital Corp. | 6.28% | 2,045,070 | $31.5M | No change |
| KVYO Klaviyo Inc. Class A | 6.10% | 1,198,270 | $30.5M | No change |
| LRMR Larimar Therapeutics Inc. | 6.06% | 3,994,468 | $30.3M | Add +17.0% |
| SLRN Acelyrin Inc. | 3.81% | 2,826,028 | $19.1M | Add +23.3% |
| EVCM Evercommerce Inc. | 3.09% | 1,641,929 | $15.5M | New |
| RPTX Repare Therapeutics Inc. | 2.94% | 3,122,499 | $14.7M | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 2.50% | 268,238 | $12.5M | Add +1.9% |
| KROS Keros Therapeutics Inc. | 2.28% | 172,633 | $11.4M | Reduce -51.0% |
| INZY Inozyme Pharma Inc. | 1.94% | 1,270,027 | $9.7M | No change |
| IRON Disc Medicine Inc. | 1.93% | 155,260 | $9.7M | Add +10.7% |
| SGMT Sagimet Biosciences Inc. Class A | 1.81% | 1,673,877 | $9.1M | Add +371.0% |
| TOST Toast Inc. Class A | 1.61% | 322,578 | $8.0M | Reduce -94.5% |
| ETWO E2OPEN Parent Holdings Inc. | 1.46% | 1,650,943 | $7.3M | No change |
| MLYS Mineralys Therapeutics Inc. | 1.40% | 541,080 | $7.0M | Reduce -4.8% |
| CMPX Compass Therapeutics Inc. | 1.12% | 2,829,712 | $5.6M | No change |
| IKENA ONCOLOGY INC | 1.10% | 3,891,118 | $5.5M | Add +99.2% |
| MLTX Moonlake Immunotherapeutics | 1.00% | 100,000 | $5.0M | Add +53.9% |
| DELL Dell Technologies -C | 0.94% | 41,245 | $4.7M | Add +17.5% |
| OMGAQ Omega Therapeutics Inc. | 0.77% | 1,055,882 | $3.9M | No change |
| AQST Aquestive Therapeutics Inc. | 0.74% | 875,000 | $3.7M | New |
| DIREXION SHS ETF TR | 0.71% | 490,000 | $3.6M | Add +44.1% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.71% | 13,319 | $3.6M | New |
| BDTX Black Diamond Therapeutics I | 0.70% | 695,000 | $3.5M | No change |
| ADCT Adc Therapeutics SA | 0.66% | 733,568 | $3.3M | No change |
| IMVT Immunovant Inc. | 0.65% | 100,000 | $3.2M | Add +66.7% |
| ENGENE HOLDINGS INC | 0.53% | 511,177 | $2.7M | Add +7.6% |
| OVID Ovid Therapeutics Inc. | 0.53% | 864,822 | $2.6M | No change |
| BRZE Braze Inc. Class A | 0.47% | 116,153 | $2.4M | Add +555.3% |
| SYRS Syros Pharmaceuticals Inc. | 0.36% | 340,855 | $1.8M | Reduce -77.2% |
| SNOW Snowflake Inc. | 0.25% | 7,819 | $1.3M | New |
| GTLB Gitlab Inc. Class A | 0.24% | 20,706 | $1.2M | New |
| BLND Blend Labs Inc. Class A | 0.23% | 361,587 | $1.2M | No change |
| GOCOQ Gohealth Inc. Class A | 0.17% | 83,264 | $875K | No change |
| DESKTOP METAL INC | 0.13% | 750,000 | $660K | No change |
| RLYB Rallybio Corp. | 0.13% | 350,240 | $648K | No change |
| ELVN Enliven Therapeutics Inc. | 0.09% | 25,000 | $440K | New |
| DTIL Precision Biosciences Inc. | 0.05% | 20,220 | $274K | No change |
| FATHOM DIGITAL MFG CORP | 0.05% | 50,000 | $231K | No change |
| UBER Uber Technologies Inc. | 0.02% | 23,918 | $79K | Add +286.6% |
Other holdings (1): bonds, preferreds, convertibles and warrants · $0 (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| PLMWF Plum Acquisition Corp. III-CW | *W EXP 03/31/202 | 666,666 | $0 | No change |
Portfolio Sells Q4 2023 → Q1 2024
| SYRS Syros Pharmaceuticals Inc. | Reduce -77.2% | 0.36% | −1.66 |
| BPMC Blueprint Medicines Corp. | Sold out | 0.00% | −1.59 |
| KROS Keros Therapeutics Inc. | Reduce -51.0% | 2.28% | −1.07 |
| ORTX Orchard Therapeutics Ltd. | Sold out | 0.00% | −0.63 |
| FRLN Freeline Therapeutics Holdin | Sold out | 0.00% | −0.13 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −0.07 |
| TOST Toast Inc. Class A | Reduce -94.5% | 1.61% | +0.16 |
| MLYS Mineralys Therapeutics Inc. | Reduce -4.8% | 1.40% | +0.23 |
| CGEM Cullinan Therapeutics Inc. | Reduce -14.5% | 9.96% | +1.63 |
Portfolio Buys Q4 2023 → Q1 2024
| ENGN Engene Holdings Inc. | Add +99.3% | 8.33% | +5.61 |
| EVCM Evercommerce Inc. | New | 3.09% | +3.09 |
| LRMR Larimar Therapeutics Inc. | Add +17.0% | 6.06% | +2.34 |
| SGMT Sagimet Biosciences Inc. Class A | Add +371.0% | 1.81% | +1.35 |
| AQST Aquestive Therapeutics Inc. | New | 0.74% | +0.74 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 0.71% | +0.71 |
| ENGENE HOLDINGS INC | Add +7.6% | 0.53% | +0.43 |
| DELL Dell Technologies -C | Add +17.5% | 0.94% | +0.30 |
| SNOW Snowflake Inc. | New | 0.25% | +0.25 |
| BRZE Braze Inc. Class A | Add +555.3% | 0.47% | +0.25 |
| GTLB Gitlab Inc. Class A | New | 0.24% | +0.24 |
| IKENA ONCOLOGY INC | Add +99.2% | 1.10% | +0.18 |
| ELVN Enliven Therapeutics Inc. | New | 0.09% | +0.09 |
| MLTX Moonlake Immunotherapeutics | Add +53.9% | 1.00% | +0.07 |
| IMVT Immunovant Inc. | Add +66.7% | 0.65% | +0.04 |
| IRON Disc Medicine Inc. | Add +10.7% | 1.93% | −0.01 |
| DIREXION SHS ETF TR | Add +44.1% | 0.71% | −0.07 |
| UBER Uber Technologies Inc. | Add +286.6% | 0.02% | −0.08 |
| SLRN Acelyrin Inc. | Add +23.3% | 3.81% | −0.28 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +1.9% | 2.50% | −0.51 |
| TRML Tourmaline Bio Inc. | Add +8.6% | 6.39% | −1.35 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 48 | $656.7M | SPCX, AKTS, CGEM, LRMR, NCDL |
| Q1 2026 | 54 | $369.9M | AKTS, LRMR, ENGN, NCDL, CGEM |
| Q4 2025Amended | 50 | $320.9M | ENGN, NCDL, OBDC, LRMR, CGEM |
| Q3 2025 | 46 | $319.9M | NCDL, OBDC, ENGN, LRMR, EVCM |
| Q2 2025 | 46 | $308.2M | NCDL, OBDC, CGEM, EVCM, TRML |
| Q1 2025 | 45 | $309.2M | NCDL, OBDC, CGEM, EVCM, TRML |
| Q4 2024 | 48 | $432.6M | NCDL, KVYO, PLRX, OBDC, CGEM |
| Q3 2024 | 68 | $514.6M | NCDL, KVYO, TRML, PLRX, CGEM |
| Q2 2024 | 40 | $359.5M | CGEM, PLRX, OBDC, KVYO, LRMR |
| Q1 2024 | 44 | $500.6M | HOOD, CGEM, PLRX, ENGN, TRML |